Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
Democratic Rep. Maxine Waters on Tuesday requested that Facebook pause its development of Libra, an upcoming cryptocurrency that the company plans to release in 2020.Technologyread more
The S&P 500 is closing in on its all-time high, and is likely to sail past it, as long as the Fed promises lower interest rates and the trade war calms down.Market Insiderread more
See which stocks are posting big moves after the bell on June 18.Market Insiderread more
President Donald Trump on Tuesday announced that he will not nominate acting Defense Secretary Patrick Shanahan to hold the position in a permanent capacity. Army Secretary...Politicsread more
But a look at state-by-state data clarifies the scale of Trump's challenge. As the president tries to rally supporters at a 2020 kickoff rally in Orlando on Tuesday, he is...Politicsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
A Bloomberg News report Tuesday morning said the White House had looked at such a move in February.Marketsread more
The order for 200 737 Max jets from British Airways parent IAG was a vote of confidence for Boeing's beleaguered aircraft following two fatal crashes.Airlinesread more
Adobe expects fiscal third-quarter earnings and revenue that are below what analysts were looking for.Technologyread more
Stocks surged after President Donald Trump said he will be meeting with his Chinese counterpart, Xi Jinping, at the upcoming G-20 summit.US Marketsread more
Swiss health care giant Roche reported a 7 percent rise in 2018 sales on Tuesday, highlighting strong demand for its new range of medicines.
Group sales climbed to 56.8 billion Swiss francs ($57.2 billion) with net income increasing by 24 percent, which included the benefits from the U.S. tax overhaul in early 2018. This beat an estimate in a Reuters poll which had predicted sales of 56.4 billion Swiss francs.
The firm said it expects revenue to grow in the low-to mid-single digit range this year and predicted that it would further increase its dividend for shareholders. Core operating profit rose by 9 percent on a constant exchange rate basis.
Roche CEO Severin Schwan told CNBC the results were "very strong" and showed "continued strong momentum" for the company. Shares climbed 1.8 percent in early deals on Thursday.
"In 2018, Roche achieved very good growth in both divisions. I am particularly pleased with the very strong demand for our new medicines, delivering significant benefit for patients fighting serious diseases like cancer, multiple sclerosis and haemophilia," he added in a statement.
Its diagnostics division saw revenue grow 7 percent during 2018 with its pharma unit growing by the same amount. It stated that key growth drivers were the new multiple sclerosis medicine Ocrevus and cancer medicines Perjeta, Tecentriq, Alecensa as well as the new haemophilia medicine Hemlibra.
Schwan said new medicines accounted for 90 percent of the firm's sales growth in 2018 and called the Ocrevus launch the "most successful" in the history of Roche.
The U.S., which has seen a greater scrutiny on drug pricing in recent years, is a key market for the pharma side of Roche. Schwan told CNBC's Julianna Tatelbaum that for that market "it's all about the value you provide patients."
"And with our research-driven, innovation-driven strategy I think we are well positioned because we can bring this real benefit to patients. And my experience is, in particular in the U.S., the society is also prepared to reward this kind of innovation. So I am confident that the United States will remain a very attractive market," he said.